Acquired Hemophilia: A Case Report of 2 Patients With Acquired Factor VIII Inhibitor Treated With Rituximab Plus a Short Course of Steroid and Review of the Literature

Abstract

Acquired hemophilia is an unusual disorder in which nonhemophiliac patients develop autoantibodies (inhibitor) against the factor VIII coagulation protein. Factor VIII inhibitor leads to life-threatening bleeding disorders classically described as new onset of diffuse bruising and prolonged partial thromboplastin time in elderly patients. Treatment is focused in the control of the acute bleeding episode and the long-term suppression of the autoantibody. Several immunosuppressive combinations have been described; however, these treatments are also associated with serious side effects that are difficult to tolerate, especially in older and debilitated patients. New treatment modalities explore the elimination of the autoantibody production by targeting B-cells with rituximab, an anti CD-20 monoclonal antibody that has shown success in a multitude of autoimmune processes. This report presents 2 patients successfully treated with rituximab and a short tapering course of steroids and focuses our discussion in the analysis of different treatment approaches available for these patients' population.

Keywords

Acquired hemophilia Factor VIII inhibitor Rituximab Immunosuppression

References

Scandella D. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII. Semin Thromb Hemost. 2002;28:291-296.

Lacroix-Desmazes S. , Kazatchkine MD , Kaveri SV Catalytic antibodies to factor VIII in haemophilia A. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S31-S34.

Green D. , Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45:200-203.

Collins P. , Macartney N. , Davies R. , Lees S. , Giddings J. , Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004;124:86-90.

Lottenberg R. , Kentro TB , Kitchens CS Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy . Arch Intern Med. 1987;147:1077-1081.

Hay CR Acquired haemophilia. Baillieres Clin Haematol. 1998;11:287-303.

Taher A. , Abiad R. , Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12:854-856.

Baudo F. de Cataldo F. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG. 2003;110:311-314.

Ries M. , Wolfel D. , Maier-Brandt B. Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VII:C inhibitor. J Pediatr. 1995;127:649-650.

10.

Castenskiold EC , Colvin BT , Kelsey SM

Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia

A. Br J Haematol. 1994;87:434-436.

11.

Stricker RB , Barlogie B. , Kiprov DD Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21:350-352.

12.

English KE , Brien WF , Howson-Jan K. , Kovacs MJ Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother. 2000;34:737-739.

13.

Brentjens RJ , Smith L. , Reich L. , Jakubowski AA Development of spontaneous factor VIII inhibitor in association with acute graft-versus-host disease. Bone Marrow Transplant. 2001;27:887-889.

14.

Sallah S. , Nguyen NP , Abdallah JM , Hanrahan LR Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med. 2000;124:730-734.

15.

Biss T. , Crossman L. , Neilly I. , Hanley J. An acquired factor VIII inhibitor in association with a myeloproliferative/ myelodysplastic disorder presenting with severe subcutaneous haemorrhage. Haemophilia. 2003;9:638-641.

16.

Komminoth A. , Dufour P. , Bergerat JP , et al. Hairy cell leukemia and factor VIII inhibitor: a case report. Nouv Rev Fr Hematol. 1992;34:269-271.

17.

Hauser I. Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost. 1999;82:1005-1007.

18.

Kessler CM An introduction to factor VIII inhibitors: the detection and quantitation . Am J Med. 1991;91(5A):1S-5S.

19.

Austen DE , Lechner K. , Rizza CR , Rhymes IL A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost. 1982;47:72-75.

20.

Delgado J. , Villar A. , Jimenez-Yuste V. , Gago J. , Quintana M. , Hernandez-Navarro F. Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects. Eur J Haematol. 2002;69:158-164.

21.

Schwartz RS , Gabriel DA , Aledort LM , Green D. , Kessler CM A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gamma-globulin. Blood. 1995;86:797-804.

22.

Reding MT , Lei S. , Lei H. , Green D. , Gill J. , Conti-Fine BM Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost. 2002;88:568-575.

23.

Spero JA , Lewis JH , Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol. 1981;48: 635-642.

24.

Ali R. , Ozcelik T. , Ozkalemkas F. , et al. Successful treatment of acquired haemophilia with prednisolone therapy. Haemophilia. 2003;9:741-743.

25.

Shaffer LG , Phillips MD Successful treatment of acquired hemophilia with oral immunosuppressive therapy . Ann Intern Med. 1997;127:206-209.

26.

Green D. , Rademaker AW , Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753-757.

27.

Lian EC , Larcada AF , Chiu AY , Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med. 1989 ;110:774-778.

28.

Burnet SP , Duncan EM , Lloyd JV , Han P. Acquired haemophilia in South Australia: a case series. Intern Med J. 2001;31:556-559.

29.

Levesque H. , Borg JY , Bossi P. , Goudemand J. , Guillet B. , Cabane J. Acquired hemophilia: current diagnostic and therapeutic approaches [in French]. Rev Med Interne. 2001; 22:854-866.

30.

Au WY , Lam CC , Kwong YL Successful treatment of acquired factor VIII inhibitor with cyclosporin. Haemophilia. 2004;10:98-100.

31.

Brox AG , Laryea H. , Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol. 1998;57:87-88.

32.

Hart HC , Kraaijenhagen RJ , Kerckhaert JA , Verdel G. , Freen M. , van de Wiel A. A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine. Transplant Proc. 1988;20(3 suppl 4):323-328.

33.

Lafferty TE Smith JB , Schuster SJ , DeHoratius RJ Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus . Arthritis Rheum. 1997;40:775-778.

34.

Zeitler H. , Ulrich-Merzenich G. , Hess L. , et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105:2287-2293.

35.

Wiestner A. , Cho HJ , Asch AS , et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426-3428.

36.

Stasi R. , Brunetti M. , Stipa E. , Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424-4428.

37.

Aggarwal A. , Grewal R. , Green RJ , et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005;11:13-19.

38.

Kain S. , Copeland TS , Leahy MF Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab) . Br J Haematol. 2002;119:578.

39.

Jy W. , Gagliano-DeCesare T. , Kett DH , et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol. 2003;109: 206-208.

40.

Fischer KG , Deschler B. , Lubbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood. 2003;101:3753-3754; author reply 3754-3755.